Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On August3, 2017, Monogram Residential Trust,Inc. (the “Company,”) issued a press release and supplemental information announcing its financial results for the quarter ended June30, 2017. The full text of the press release and the supplemental information are furnished as Exhibit99.1 and Exhibit99.2, respectively. Additionally, the Company has posted a copy of the press release and the supplemental information on its website at www.monogramres.com.

The information in this Item 2.02 of this Current Report on Form8-K and the attached Exhibit99.1 and Exhibit99.2 are furnished to Item 2.02 of Form8-K and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall the information be deemed incorporated by reference in any filing under the Securities Act of 1934, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits:

ExhibitNo.

Description

99.1

Press Release, dated August3, 2017

99.2

Supplemental Information for the quarter ended June30, 2017


Monogram Residential Trust, Inc. Exhibit
EX-99.1 2 a17-18852_1ex99d1.htm EX-99.1 Exhibit 99.1     MONOGRAM RESIDENTIAL TRUST ANNOUNCES SECOND QUARTER 2017 RESULTS   PLANO,…
To view the full exhibit click here

About Inc. (NASDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.